ArticleThe EMBO journal2013
Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis.
Article in The EMBO journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 438 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
438 citing papers in PubMed, 712 citations in OpenAlex.
- Inflammation-Induced Claudin-2 Up-Regulation Limits Pancreatitis Development by Enhancing Pancreatic Ductal Transport.Gastroenterology · 2026Article
- Planar neural organoids as an advanced in vitro model to study patient-derived melanoma metastasis.Scientific reports · 2026Article
- New developments and applications of human organoids.Nature reviews. Molecular cell biology · 2026Review
- Pancreatic organoids and organoid-on-a-chip platforms: from disease modeling to precision therapy.Journal of translational medicine · 2026Review
- Organoids: From Bench to Bedside Applications.MedComm · 2026Review
- Tumor organoid platform design for drug response modeling: culture architecture, microenvironmental complexity, and AI-assisted readouts.Archives of pharmacal research · 2026Review
- Article
- Progress and challenges in the development of advanced pancreatic cancer organoids.Journal of experimental & clinical cancer research : CR · 2026Review
- Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer.Nature cancer · 2026Article
- Adult canine pancreatic organoids enable functional analysis of pancreatic epithelial barrier and inflammatory responses.BMC molecular and cell biology · 2026Article
- Cancer-selective photoimmunotherapy spares T cells and NK cells and promotes antitumor immunity in an allogeneic human 3D culture model.Photochemistry and photobiology · 2026Article
- Organoid-based systems for biomedical innovation: advances in disease modeling, drug screening, and precision medicine.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Organoid Technology as a Promising Frontier in Organ Transplantation and Regenerative Medicine.International journal of stem cells · 2026Review
- Reconstructing the Islets: Advances in 3D Pancreatic Organoid Models for Functional β-Cell Replacement.International journal of molecular sciences · 2026Review
- Cystic Fibrosis of the Pancreas: In Vitro Duct Models for CFTR-Targeted Translational Research.International journal of molecular sciences · 2026Review
- Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations.Signal transduction and targeted therapy · 2026Article
- Advances in liver and pancreas organoids: how far we have come and where we go next.Nature reviews. Gastroenterology & hepatology · 2026Review
- AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids.Frontiers in pharmacology · 2026Article
- Review
- A convective transport-enhanced multi-organoid device for therapeutic modeling of the liver-pancreas axis in obesity.Theranostics · 2026Article
378 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 2 countries.
Funding
Abstract
Lgr5 marks adult stem cells in multiple adult organs and is a receptor for the Wnt-agonistic R-spondins (RSPOs). Intestinal, stomach and liver Lgr5(+) stem cells grow in 3D cultures to form ever-expanding organoids, which resemble the tissues of origin. Wnt signalling is inactive and Lgr5 is not expressed under physiological conditions in the adult pancreas. However, we now report that the Wnt pathway is robustly activated upon injury by partial duct ligation (PDL), concomitant with the appearance of Lgr5 expression in regenerating pancreatic ducts. In vitro, duct fragments from mouse pancreas initiate Lgr5 expression in RSPO1-based cultures, and develop into budding cyst-like structures (organoids) that expand five-fold weekly for >40 weeks. Single isolated duct cells can also be cultured into pancreatic organoids, containing Lgr5 stem/progenitor cells that can be clonally expanded. Clonal pancreas organoids can be induced to differentiate into duct as well as endocrine cells upon transplantation, thus proving their bi-potentiality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.